Clearly the Amgen deal was backloaded and probably payments dependent on positive data as well. The fact the company is struggling this badly, and they haven’t come in to buy it all outright, speaks volume to the contract they have in place. Again probably a poorly done one by our lovely CEO at the time. If any near term cash possible from that deal then they wouldn’t have needed the last dilution. They clearly well protected
News 
Market Data 
Discover 
